Excision BioTherapeutics Announces Data from the Phase 1/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B

As First in Human Study, EBT-101-001 provided invaluable insights on the potential of CRISPR to address infectious diseases impacting millions of people